UroGen Pharma Announces June 2021 Conference Schedule

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN) will present at two virtual healthcare conferences in June 2023. The Jefferies Virtual Healthcare Conference is on June 2 at 11:30 AM ET, and the Goldman Sachs 42nd Annual Global Healthcare Conference is on June 9 at 8:50 AM ET. Live webcasts will be available on UroGen's website, with replays accessible for approximately 30 days. UroGen focuses on treating specialty cancers and urologic diseases, developing innovative treatments like RTGel™ and UGN-102 for bladder cancer.

Positive

• Presentation at two major virtual healthcare conferences, enhancing visibility and investor engagement.
• Focus on innovative treatments for specialty cancers and urologic diseases such as RTGel™ and UGN-102.

Negative

• None.

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in June:

Jefferies Virtual Healthcare Conference

• Wednesday, June 2
• 11:30 AM Eastern Time

Goldman Sachs 42nd Annual Global Healthcare Conference

• Wednesday, June 9
• 8:50 AM Eastern Time

A live webcast of each event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of each webcast will be available on the website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005088/en/

FAQ

What conferences will UroGen Pharma present at in June 2023?

UroGen Pharma will present at the Jefferies Virtual Healthcare Conference on June 2 and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9.

What time will UroGen's presentations take place?

The Jefferies conference presentation is scheduled for June 2 at 11:30 AM ET, and the Goldman Sachs conference presentation is on June 9 at 8:50 AM ET.

How can I access the UroGen conference presentations?

Live webcasts of UroGen's presentations will be available on their website, with replays accessible for about 30 days.

What is UroGen's focus in the biopharmaceutical industry?

UroGen is dedicated to building novel solutions for treating specialty cancers and urologic diseases.

What is RTGel™ and its significance?

RTGel™ is a proprietary sustained release, hydrogel-based platform technology developed by UroGen to improve drug delivery in urologic treatments.